Hansa Biopharma AB Stock: price and insider trades · Sweden

Headquartered in Lund, Sweden, Hansa Biopharma AB belongs to the Health Care sector and traces its origins to 2007. Filings by its managers are published through Finansinspektionen. The last twelve months, up to 18 October 2026, brought 10 filings signed by 4 insiders.

On the market, 3 insiders bought (3 purchases totalling €208k) while 1 insider sold (7 sales totalling €2.7M). Netting one side against the other leaves €2.5M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 board member, 1 finance chief and 1 chief executive. Michael Bologna filed the largest sale, €927k, on 29 July 2026, which represents 0.31% of the company's market value.

The clock since the last published purchase (28 September 2026) now reads 19 days. Typically, a trade is published a median of 3 days after it takes place. Under the Market Abuse Regulation, managers have three business days to notify their trades. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

For context, the typical company on the same exchange (median of 890 companies) published 7 filings over the same period, against 10 filings here. Over the whole record (from 2021), the tally stands at 7 purchases and 8 sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.